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Abstract
Background: Chronic inflammatory demyelinating polyneuropathy (CIDP) is presented by a large heterogeneity
of clinical phenotypes. Around 50% of patients suffer from typical CIDP and show better therapy response than
atypical variants. The goal of our study was to search for cellular immunological differences in typical versus
atypical CIDP in comparison to controls.
Methods: We evaluated 26 (9 typical, 17 atypical) patients with mainly active-unstable CIDP using clinical and
immunological examinations (enzyme-linked immunospot assay ELISPOT, fluorescence-activated cell sorting
FACS) in comparison to 28 healthy, age-matched controls (HC). Typical or atypical CIDP measurements were
compared with HC using Kruskal-Wallis test.
Results: Atypical CIDP patients showed increased frequencies of T cell subsets, especially CD4+ effector memory
T cells (TEM) and CD4+ central memory T cells (TCM) as well as a tendency of higher T cell responses against the
peripheral myelin antigens of PMP-22, P2, P0 and MBP peptides compared to typical CIDP. Searching for novel
auto-antigens, we found that T cell responses against P0 180-199 as well as MBP 82-100 were significantly elevated in
atypical CIDP patients vs. HC.
Conclusions: Our results indicate differences in underlying T cell responses between atypical and typical CIDP
characterized by a higher peripheral myelin antigen-specific T cell responses as well as a specific altered CD4+
memory compartment in atypical CIDP. Larger multi-center studies study are warranted in order to characterize
T cell auto-reactivity in atypical CIDP subgroups in order to establish immunological markers as a diagnostic tool.
Keywords: Chronic inflammatory demyelinating polyneuropathy, T memory subsets, MBP protein, P0 protein,
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Background
Chronic inflammatory demyelinating polyneuropathy
(CIDP) is the most common autoimmune peripheral
neuropathy but remains a rare disease with a prevalence
of 0.8-8.9 cases per 100.000 [1, 2]. The disorder causes
severe disability in more than 50% of the patients in a
chronic-progressive course [1]. Diagnosis can be difficult
given the heterogeneity of CIDP phenotypes. About 50%
of the patients suffer from so-called atypical variants
including Distal Acquired Demyelinating Polyneuropathy
(DADS) in 25-35% of the cases, Multifocal Acquired
Demyelinating Sensory And Motor Polyneuropathy
(MADSAM) in 15% and rare variants such as pure sensory
CIDP (10-13%), pure motor CIDP (<10%) and focal CIDP
(2%) [3]. These CIDP subtypes are likely to differ with
respect to underlying pathomechanisms and may ne-
cessitate different treatment approaches.
Despite recent progress, the underlying immunopatho-
genetic mechanisms remain poorly understood [4]. Both
humoral as well as cellular immune responses are likely
to play a role in the induction of autoimmune neuroin-
flammation, which leads to demyelination and axonal
degeneration [4–7].* Correspondence: juliane.klehmet@charite.de1Department of Neurology, Charité University Medicine, Charitéplatz 1, 10117
Berlin, Germany
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Staudt et al. BMC Neurology  (2017) 17:81 
DOI 10.1186/s12883-017-0860-z
Peripheral myelin antigens are promising auto-antigens
in CIDP pathogenesis. Recently, we demonstrated higher
frequencies of auto-reactive IFN-γ responses directed
against the peripheral myelin antigens PMP-22 and P2 in
treatment naïve patients who responded subsequently well
to intravenous immunoglobulin (IVIG) treatment. Clinical
improvement under IVIG-treatment correlated with the
reduction of antigen-specific responses against PMP-22
and P2 [8].
Experimental studies in the EAN model of Guillain-Barré-
Syndrom (GBS) support a pathogenic role of another com-
pact myelin P0. Immunization with P0 180-199 is capable to
induce EAN in wildtype-, IFN-γ knockout and TNF-α
knockout mice [9–11]. However, an evaluation in CIDP
patients remains to be done.
Myelin basic protein (MBP) is a major constituent of the
myelin sheath in the central and peripheral nervous system
[12]. Whereas it has been established as an immunodomi-
nant auto-antigen for demyelination in the immunopatho-
genesis of Multiple Sclerosis (MS) its auto-reactive potential
in CIDP remains elusive [13].
T cells can be differentiated into CD45RA+ CCR7+ naïve,
CD45RA- CCR7- effector memory (TEM), CD45RA-
CCR7+ central memory (TCM) and CD45RA+ CCR7-
terminally differentiated effector memory (TEMRA) T
cells [14]. Especially CD4+ T cells play a major role in
CIDP immunopathogenesis [15–17]. In blood and CSF
of CIDP patients, significantly elevated frequencies of
CD4+ TEM and CD4+ TCM were demonstrated, whereas
long-term treated CIDP patients showed significantly re-
duced CD4+ memory subsets in contrast to untreated CIDP
patients [17–19].
Here, we hypothesize that autoreactive myelin-specific
T cell responses as well as T cell memory subsets differ
between atypical and typical manifestations of CIDP.
Methods
Patients
We evaluated 26 CIDP patients using clinical and im-
munological (enzyme-linked immunospot assay ELISPOT,
fluorescence-activated cell sorting FACS) examinations in
comparison to 28 healthy, age-matched controls. CIDP
patients who met the diagnostic criteria of European
Federation of Neurological Sciences (EFNS) 2010 were
divided into “typical” vs. “atypical” according to EFNS 2010
[20]. Therapy response was defined as an improvement of
≥2 in Medical Research Council (MRC) sum score in 2 dif-
ferent muscle groups, an improvement of ≥1 in Inflamma-
tory Neuropathy Cause and Treatment (INCAT) score
(excluding changes in arm function from 0 to 1) or alterna-
tively an improvement of ≥50% of the walking distance as
described previously [8]. Patients and controls were re-
cruited in the outpatient clinic of the Department of
Neurology, Charité University Medicine Berlin.
Peripheral myelin antigens
ELISPOT assay was performed using peptides of seven
peripheral myelin antigens and CEF as positive control
for T cell responses (Table 1). CEF is a peptide pool
containing 23 MCH class 1 restricted viral antigens [21].
Peripheral myelin antigens were provided by Dr. R.
Volkmer, Institute of Medical Immunology, Charité
University Medicine Berlin. CEF was provided by JPT
Peptide Technologies GmbH, Berlin.
Cryopreservation of Peripheral Blood Monocytes (PBMC)
To evaluate T cell responses efficiently we preserved
PBMC in liquid nitrogen over a maximum of 6 months.
Blood was sampled in CPT tubes for ELISPOT and in
EDTA tubes for flow cytometry. PBMC were isolated
within 2 h after venipuncture by 1500 g centrifugation
for 20 min. After washing, we diluted the PBMC at a
concentration of 2x107cells/ml in freezing medium A
(60% FCS; 40% RPMI, Biochrom, Berlin, Germany) at 4 °C.
The same volume of freezing medium B (20% DMSO, 80%
FCS) at 4 °C was added before cell suspensions were trans-
ferred into cryovials (Sarstedt, Nürnbrecht, Germany) and
set in one at 4 °C prechilled Nalgene Cryogenic Freezing
Container (Fisher Scientific, Hannover, Germany) which
was placed in −80 °C overnight. After 12-24 h, cryovials
were transferred into liquid nitrogen tanks for storage until
ELISPOT.
Thawed cell suspensions were transferred into a 15 ml
tube containing 10 ml of ice cold PBS. After two washing
steps, cells were pipetted in complete RPMI medium (93%
RPMI-1640. 5% heat-inactivated FCS, 1% L-glutamin, 1%
penicillin-streptomycin) and counted manually using
Trypan blue-staining and light microscopy.
ELISPOT
IFN-γ ELISPOT assay in this study was performed on
human PBMC as previously described [8]. We plated
4×105cells/well in triplicates for each antigen and posi-
tive (CEF) or negative control (medium). CEF, a peptide
pool containing viral antigens functioning as a positive
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The peripheral myelin antigens PMP-22 32-51, PMP-22
51-64, PMP-22 120-133, P2 14-25, P2 61-70 were used
at 40 μg/ml and P0 180-199, MBP 82-100 were used at
20 μg/ml. Spot counts were analyzed via ELISPOT Reader
Immunospot (CTL Analyzers, Cleveland, Ohio, USA) and
custom software. Spot forming units (SFU) for each
antigen were subtracted by SFU of spontaneous IFN-γ
secretion (usually <5) and then calculated for a cell
amount of 106 cells.
FACS
Flow cytometry analyses were performed on lymphocyte-
and T cell-subpopulations in EDTA whole blood within
12 h after venipuncture.
Flow cytometric analysis was performed as we described
recently [17]. Briefly, mouse anti-human fluorescently
labelled monoclonal antibodies allowed to quantifying
the frequencies of lymphocyte and T cell subpopulations.
The following antibodies were used: CD3 Allophycocyanine-
Alexa Fluor 750 (APC-A750), CD4 energy coupled dye
(ECD), CD8 APC, CD14 Fluorescein isothiocyanate
(FITC), CD16 Phycoerythrine (PE), CD19 PE-Cy5.5,
CD56 PE, CD45RA Pacific-Blue (PB), CD45 Krome-
Orange (KrO) (all by Beckman Coulter) and CCR7
Phycoerythrine (PE) (R&D Systems). Stained samples
were evaluated on a ten-colour Navios flow cytometer
and were analyzed using Navios Software (Beckman
Coulter).
Statistics
All statistical tests were performed using GraphPadPrism
6.0 software. The study was assessed as an exploratory
analysis. Typical or atypical CIDP measurements were
compared with healthy, age-matched controls (HC) using
Kruskal-Wallis test followed by post-hoc unpaired t-test
or Mann-Whitney-test when p < 0.05. For group differ-
ences with regard to sex, prior treatment, disease activity
and therapy response, Fisher’s exact test was used. For age
and INCAT score, unpaired t-test was used. For time since
diagnosis, Mann-Whitney-test was used. Level of signifi-
cance was defined as p < 0.05 for all comparative tests.
Results
Clinical characterization of typical and atypical CIDP
patient group (Table 2)
We recruited 17 (65.4%) male and nine (35.6%) female
patients. Mean age was 59 years (range 32-78). 20/26
(76.9%) patients were included in active-unstable stages
of the disease, 1 (3.8%) with active-stable CIDP and five
(19.2%) in clinical remission [22]. 12 (46.2%) patients
were treatment naïve whereas 10 (38.5%) received IVIG
therapy and four (15.4%) glucocorticosteroids (GS)
prior to our study. We classified 9 (38.5%) as typical
and 17 (61.5%) as atypical CIDP patients, including 6
with pure sensory CIDP, 4 with MADSAM, 5 with
DADS, 1 with pure motor CIDP and 1 with a sensory-
ataxic course of disease.
Therapy-responders were classified as 9/9 (100%) typical
and only 8/17 (47%) atypical CIDP patients. As controls we
used age-matched, healthy patients (HC). For ELISPOT-
analyses 14 HC (mean age 70, range 53-83) and for FACS-
analyses 28 HC (mean age 61, range 42-83) were evaluated.
T cell IFN-γ- responses to P0 180-199 and MBP 82-100 were
elevated in CIDP patients compared to healthy controls
T cell responses against the peripheral myelin antigens,
P0 180-199 and MBP 82-100 were measured by IFN-γ
ELISPOT in a cohort of 26 CIDP patients. Due to spon-
taneous IFN-γ-production, 6 patients (1 typical, 5 atyp-
ical) were excluded for further ELISPOT analysis.
T cell responses against P0 180-199 as well as MBP
82-100 were significantly elevated in CIDP patients vs.
HC: P0 180-199 (p < 0.05), MBP 82-100 (p < 0.001)
(Fig. 1). CEF-specific IFN-γ-production in CIDP did
not differ from HC excluding unspecific T cell activa-
tion in CIDP.
Increased myelin antigen-specific T cell responses in atypical
CIDP
Atypical CIDP variants tended to have increased IFN-γ
responses to all 7 tested peripheral myelin antigens com-
pared to both, typical CIDP patients and HC (Fig. 2).
This difference between typical and atypical CIDP patients
was more pronounced for PMP-22 32-51 (p = 0.0621),
PMP-22 51-64 (p = 0.1050), PMP-22 120-130 (p = 0.1451),
P0 180-199 (p = 0.1894) and MBP 82-100 (p = 0.1841)
(Fig. 2). In comparison to HC, atypical CIDP patients
showed significantly higher SFU for the following periph-
eral myelin antigens: PMP-22 32-51 (patypical < 0.05), PMP-
22 51-64 (patypical < 0.01), PMP-22 120-130 (patypical < 0.01),
P2 14-25 (patypical < 0.01), P0 180-199 (patypical < 0.05), MBP
82-100 (patypical < 0.01) (Fig. 2). CEF responses did not differ
between tested groups.
Atypical CIDP variants have significantly higher levels of
Cd4+ memory T cells
Frequencies of T cells (p < 0.01) and CD4+ T cells
(p < 0.001) were higher in patients with atypical CIDP
variants in comparison to typical CIDP patients (Fig. 3a).
Investigating CD4+ Tcell subpopulations, CD4+ memory
Tcell subsets were significantly increased in atypical vs. typ-
ical CIDP patients, as shown for CD4+ TEM (p < 0.05) and
CD4+ TCM (p < 0.01) in Fig. 3b.
Likewise CD8+ TEM (p = 0.1745) and CD8+ TCM
(p = 0.1475) tended to be increased in atypical compared
to typical CIDP patients. Further compared to HC, atypical
CIDP patients had significantly elevated CD8+ TCM-
frequencies (p < 0.05) (Fig. 3c).
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Discussion
In the present study, typical CIDP differed from the group
of atypical variants. Here, we found a stronger activated
immune system in patients suffering from atypical variants
of CIDP defined by a trend towards increased peripheral
myelin antigen-specific (PMP-22, P0 180-199, MBP 82-
100) T cell responses associated with a specific altered
CD4+ memory compartment of increased CD4+ TEM
and CD4+ TCM counts in the blood. Further we detected
elevated T cell responses against antigens P0 180-199 and
MBP 82-100 in CIDP patients which have not described
before.
We confirmed or previous findings that changes of the
T memory compartment is a common finding especially
Fig. 1 Frequency of P0 and MBP specific T cells in CIDP patients. Frequencies of peripheral myelin antigen-specific T cell responses in CIDP
patients (n = 20) vs. HC (n = 14) measured by IFN-y ELISPOT. Background corrected SFU per 106 PBMC were significantly elevated for P0 180-199
as well as MBP 82-100 in CIDP patients vs. HC. Maximum value defined due to methodical limitations (CEF = 2500). (*p < 0.05, **p < 0.01,
***p < 0.001). Scatter dot plot with line at mean
Table 2 Clinical information (n = 26; IVIG intravenous immunoglobulins, CIDP chronic inflammatory demyelinating polyneuropathy,
INCAT Inflammatory Neuropathy Cause and Treatment, GS glucocorticosteroids)
typical atypical p-values atypical vs. typical
Sex male 3/9 (33%) 14/17 (82%) 0.013
female 6/9 (66%) 3/17 (18%)
Age (years) mean 61.0 57.2 0.512
range 32-78 33-74
Previous treatment None 3/9 (33%) 9/17 (53%) 0.429a
IVIG 4/9 (44%) 6/17 (35%) 0.652a
Steroid 2/9 (22%) 2/17 (12%) 0.547a
Time since diagnosis mean 4.1 4.2 0.860
(years) range 1-8 1-7
INCAT mean 3.2 2.3 0.045
Range <1-8 <1-7
Disease activity range 1-5 1-3
active-unstable 6/9 (66%) 14/17 (82%) 1.000b
active-stable 1/9 (11%) 0/17 (0%) 0.333b
in remission 2/9 (22%) 3/17 (18%) 1.000b
Therapy response responder 9/9 (100%) 8/17 (47%) 0.022
non-responder 0/9 (0%) 9/17 (53%)
Fishers exact test for sex, previous treatment, disease activity and therapy response
acompared versus treatment naïve patients
bcompared versus remission state; unpaired t-test for age and INCAT score; Mann-Whitney test for time since diagnosis
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in untreated patients [8, 17], which is in contrast to
Sanvito and colleagues who showed no differences in T
cell subpopulation [23]. In the present study, we de-
tected elevated TEM and TCM primarily in atypical
CIDP patients. Clinical experience and studies suggest
that typical CIDP patients respond better to therapy than
atypical CIDP variants, especially DADS [24], which is in
line with our presented data showing that 100% (9/9) of
typical compared to 47% (8/17) of atypical CIDP patients
were therapy-responders. The reason for different treat-
ment responses of CIDP subtypes remains unknown. The
higher specific immune responses against myelin-derived
peptides in atypical compared to typical variants may be a
cause for the lower treatment-responses. Likewise, the in-
creased immune reactivity in atypical CIDP patients could
result from insufficient treatment.
Recently, it has been demonstrated that CIDP patients
show a diminished pro-regenerative function of Schwann
cells leading to the axonal loss and therefore incomplete
clinical recovery after treatment which is probably caused
by inflammatory mediators [25]. Thus, differences in im-
mune responses between typical and atypical CIDP we
have demonstrated might also influence Schwann cell
function resulting in different treatment responses and
long-term outcome. The INCAT score was significantly
lower in atypical cases. However, there was no difference
in the time since diagnosis so that a longer disease course
and hence pronounced disability and/or altered immune
response is not the cause of this difference. Yet, we in-
cluded mainly atypical case with mild motoric disability (6
patients with sensory CIDP [35.3%] and 5 patients with
DADS [29.4%]) who are less often dependent on walking
aids leading to lower INCAT disability scores.
Since we included mainly clinically unstable patients
who had partly received treatment before, we are not
able to answer this question at present. Based on previous
results of reduced CD4+ memory subsets in GS-treated
patients [17], it might be further argued that GS treatment
may be efficient for this patient group. In contrast to
Sanvito et al. [26], we identified higher IFN-γ responses to
P2 and PMP22 peptides which have been more pro-
nounced in the atypical compared to the typical CIDP
subgroup. A higher number and proportion of atypical
patients might explain this discrepancy as well as the fact
that we included mainly clinically unstable and newly di-
agnosed patients.
Earlier publications detected P0 IgG-antibodies in
CIDP patients and P0 180-199 specific T cell re-
sponses in spontaneous autoimmune polyneuropathy-
Fig. 3 Quantitative analysis of lymphocyte subpopulations in typical versus atypical CIDP. Lymphocyte subpopulations of typical (n = 9) vs.
atypical CIDP patients (n = 17) vs. HC (n = 28) were measured by flow cytometry. In atypical CIDP patients significantly higher frequencies of T
cells and CD4+ T cells were seen compared to vs. typical CIDP patients and HC (a). Significantly higher frequencies for CD4+ TEM and TCM in
atypical vs. typical CIDP patients and HC (b). Significantly higher frequencies for CD8+ TCM in atypical CIDP patients vs. HC (c). (*p < 0.05,
**p < 0.01, ***p < 0.001). Scatter dot plot with line at mean
Fig. 2 Frequencies of peripheral myelin antigen-specific T cell
responses in typical versus atypical CIDP patients. Typical (n = 8) vs
atypical CIDP patients (n = 12) vs. HC (n = 14) were measured by IFN-y
ELISPOT. Background corrected SFU per 106 PBMC. Significantly, elevated
SFU were observed in atypical CIDP patients vs. HC for PMP-22 32-51,
PMP-22 51-64, PMP-22 120-133, P2 14-25, P0 180-199, MBP 82-100.
(*p < 0.05, **p < 0.01, ***p < 0.001). Scatter dot plot with line at mean.
For P0 180-199, a cut-off value of 5 SFU/106 PBMC in T cell-Elispot having
a sensitivity of 91,7% (11/12) and a specificity of 62,5% (5/8) with AUC
0.69. For MBP 82-100 using a cut-off value of 10 SFU per 106 PBMC in a T
cell-Elispot assay had a sensitivity of 75,0% (9/12) and a specificity
of 62,5% (5/8) with AUC 0.68
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mice [11]. Although EAN resembles Guillain-Barré-
Syndrom (GBS) much more than CIDP, we regarded
P0 as possible further candidate autoantigen of com-
pact myelin for CIDP. Here, we detected elevated P0
180-199 specific T cell responses primarily in atypical
CIDP.
Up to now, only little is known about the role of
MBP 82-100 in the pathogenesis of CIDP even though
MBP has been detected as part of the myelin sheath of
peripheral nerves. Nevertheless, there is long-standing
evidence that MBP 82-100 can induce neuroinflamma-
tion in autoimmune diseases [27]. Glatirameracetat,
known antagonist of MBP 82-100 specific T cell recep-
tor and part of MS therapy has been demonstrated to
alleviate symptoms also in EAN- mice [28, 29]. Here,
we demonstrated significantly elevated MBP 82-100
specific T cell responses in CIDP patients, again pri-
marily in patients with atypical manifestations.
There is growing evidence for the autoimmune po-
tential of antigens which are derived from non-compact
myelin of the nodal/paranodal region such as neurofas-
cin 155 of 186 leading to antibody response in distinct
subgroups of CIDP or multifocal motoric neuropathy
(MMN) [30–33]. Thus, antigenic targets derived from
both compact and non- compact myelin leading to hu-
meral and/or cellular immune response may define
underlying immune mechanism of different clinical
phenotypes of CIDP.
Several limitations may have affected our results. First,
our clinically heterogeneous group of atypical patients
was too small to distinguish between subgroups of atypical
CIDP, which would be necessary to characterize atypical
subtypes and to define specific cut offs for our immuno-
logical parameters. Second, differences in gender and
INCAT score between typical and atypical CIDP patients
might have influenced our immunological findings. Third,
we aimed to recruit treatment-naïve patients in active-
unstable stages of the disease. However, only 46% of
patients (12/26) were treatment-naïve at enrollment. Pre-
vious immunosuppressive and –modulating therapy might
have influenced our immunological findings.
Conclusions
Higher myelin-antigen specific T cell responses together
with elevated T cell memory subsets were found in atypical
compared to typical CIDP patients suggesting different
patterns of immune responses in clinically distinctive CIDP
subgroups. Myelin as well as nodal/paranodal proteins
might serve as candidate autoantigens to establish ro-
bust immune markers for CIDP subtype differentiation.
Given the clinical diversity of CIDP a larger cohort
study is warranted in order to establish those markers
with reliable cut-off values.
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